EUVIMEDEUVIMED entdecken
Crossref

Patents, Innovation, and Competition in Pharmaceuticals: The Hatch-Waxman Act After 40 Years

C. Scott Hemphill, Bhaven N. Sampat

Journal of Economic Perspectives · 01.05.2025 · 39 (2) · 27-52

DOI: 10.1257/jep.20241423 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Economic Perspectives, erschienen am 01.05.2025. Verfasst von C. Scott Hemphill und 1 weiteren Autor:innen. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 81 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A central policy issue in pharmaceuticals is how to balance the dynamic benefits of new drugs against the static benefits of low prices for existing drugs. In the United States, that balance is set by the Hatch-Waxman Act. We review the Act's origins and key features, then present evidence on its effects on competition and innovation. On the competition side, we show how the Act creates incentives for brands to accumulate patents and generics to challenge them, with the result being a rough stalemate. We also discuss strategies deployed by brands to delay generic entry. On the innovation side, we show that the Act's patent extension provisions — which aim to allow branded firms to make up for time lost during clinical trials and regulatory review — are incomplete, resulting in potential distortions. The net result is a convoluted and expensive approach to balancing innovation and competition.

Zitieren

APA

Hemphill, C. S., & Sampat, B. N. (2025). Patents, Innovation, and Competition in Pharmaceuticals: The Hatch-Waxman Act After 40 Years. Journal of Economic Perspectives, 39(2), 27-52. https://doi.org/10.1257/jep.20241423

Vancouver

Hemphill CS, Sampat BN. Patents, Innovation, and Competition in Pharmaceuticals: The Hatch-Waxman Act After 40 Years. Journal of Economic Perspectives. 2025;39(2):27-52. doi:10.1257/jep.20241423

BibTeX
@article{Hemphill2025,
  author = {Hemphill, C. Scott and Sampat, Bhaven N.},
  title = {Patents, Innovation, and Competition in Pharmaceuticals: The Hatch-Waxman Act After 40 Years},
  journal = {Journal of Economic Perspectives},
  year = {2025},
  volume = {39},
  number = {2},
  pages = {27--52},
  doi = {10.1257/jep.20241423}
}
Kostenlos starten →